News
Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback